Exousia Pro Offers Guidance on New Subdivisions
Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has announced the formation of new subdivisions to expand its plant-based exosome technology beyond cancer therapies. The company is establishing three wholly owned subsidiaries:
- Biotech: Focused on cancer therapies using exosomes
- Cosmeceutical: Targeting the skincare industry with two studies in progress
- Nutraceutical: Developing exosome-enhanced anti-aging supplements, IV therapies, tinctures, and peptides in a market valued at $73-85 billion (2024/2025)
The company plans to enter these markets through joint ventures with established companies, enhancing their products with plant-based exosomes. Exousia Pro is also in final negotiations for a licensing deal that would enable entry into four additional markets.
Exousia Pro (OTCPINK:MAJI), un'azienda biotecnologica in fase clinica, ha annunciato la creazione di nuove divisioni per espandere la sua tecnologia di esosomi a base vegetale oltre le terapie oncologiche. L'azienda sta costituendo tre filiali interamente controllate:
- Biotech: specializzata nelle terapie oncologiche con esosomi
- Cosmeceutica: rivolta all'industria della cura della pelle con due studi in corso
- Nutraceutica: sviluppo di integratori anti-invecchiamento potenziati con esosomi, terapie endovenose, tinture e peptidi, in un mercato valutato tra 73 e 85 miliardi di dollari (2024/2025)
L'azienda prevede di entrare in questi mercati attraverso joint venture con aziende consolidate, migliorando i loro prodotti con esosomi di origine vegetale. Exousia Pro è inoltre in trattative finali per un accordo di licenza che permetterebbe l'ingresso in altri quattro mercati.
Exousia Pro (OTCPINK:MAJI), una empresa biotecnológica en fase clínica, ha anunciado la creación de nuevas divisiones para expandir su tecnología de exosomas de origen vegetal más allá de las terapias contra el cáncer. La compañía está estableciendo tres filiales de propiedad total:
- Biotech: enfocada en terapias contra el cáncer utilizando exosomas
- Cosmeceútica: dirigida a la industria del cuidado de la piel con dos estudios en curso
- Nutracéutica: desarrollando suplementos anti-envejecimiento potenciados con exosomas, terapias intravenosas, tinturas y péptidos en un mercado valorado entre 73 y 85 mil millones de dólares (2024/2025)
La empresa planea entrar en estos mercados mediante joint ventures con compañías consolidadas, mejorando sus productos con exosomas de origen vegetal. Exousia Pro también está en negociaciones finales para un acuerdo de licencia que permitirá el ingreso a cuatro mercados adicionales.
Exousia Pro (OTCPINK:MAJI)는 임상 단계의 바이오테크 기업으로, 식물 기반 엑소좀 기술을 암 치료를 넘어 확장하기 위해 새로운 자회사를 설립했다고 발표했습니다. 회사는 세 개의 완전 자회사 설립을 추진하고 있습니다:
- 바이오텍: 엑소좀을 활용한 암 치료에 집중
- 코스메슈티컬: 피부 관리 산업을 대상으로 두 건의 연구 진행 중
- 뉴트라슈티컬: 엑소좀 강화 항노화 보충제, 정맥 주사 치료, 팅크 및 펩타이드 개발, 2024/2025년 기준 730억~850억 달러 규모 시장
회사는 기존 기업과의 합작 투자를 통해 이 시장에 진입할 계획이며, 식물 기반 엑소좀으로 제품을 향상시킬 예정입니다. 또한 Exousia Pro는 4개의 추가 시장 진입을 위한 라이선스 계약을 최종 협상 중에 있습니다.
Exousia Pro (OTCPINK:MAJI), une entreprise biotechnologique en phase clinique, a annoncé la création de nouvelles filiales pour étendre sa technologie d'exosomes d'origine végétale au-delà des thérapies contre le cancer. La société établit trois filiales détenues à 100 % :
- Biotech : spécialisée dans les thérapies contre le cancer utilisant des exosomes
- Cosmécutique : ciblant l'industrie des soins de la peau avec deux études en cours
- Nutraceutique : développement de compléments anti-âge améliorés par des exosomes, thérapies intraveineuses, teintures et peptides sur un marché estimé entre 73 et 85 milliards de dollars (2024/2025)
La société prévoit d’entrer sur ces marchés via des coentreprises avec des entreprises établies, en améliorant leurs produits grâce aux exosomes d’origine végétale. Exousia Pro est également en négociations finales pour un accord de licence qui permettrait d’accéder à quatre marchés supplémentaires.
Exousia Pro (OTCPINK:MAJI), ein biotechnologisches Unternehmen in der klinischen Phase, hat die Gründung neuer Tochtergesellschaften angekündigt, um seine pflanzenbasierten Exosom-Technologien über Krebstherapien hinaus auszubauen. Das Unternehmen gründet drei vollständig im Eigentum befindliche Tochterfirmen:
- Biotech: Fokus auf Krebstherapien mit Exosomen
- Cosmeceutical: Ausrichtung auf die Hautpflegebranche mit zwei laufenden Studien
- Nutraceutical: Entwicklung von exosomverstärkten Anti-Aging-Ergänzungsmitteln, IV-Therapien, Tinkturen und Peptiden in einem Markt mit einem Wert von 73 bis 85 Milliarden US-Dollar (2024/2025)
Das Unternehmen plant, diese Märkte durch Joint Ventures mit etablierten Firmen zu betreten und deren Produkte mit pflanzenbasierten Exosomen zu verbessern. Exousia Pro befindet sich außerdem in finalen Verhandlungen über eine Lizenzvereinbarung, die den Eintritt in vier weitere Märkte ermöglichen würde.
- Diversification into multiple high-value markets (skincare, nutraceuticals)
- Two skincare studies nearing completion
- Planned expansion into four additional markets through licensing deal in final stages
- Strategic approach through joint ventures reduces market entry risks
- Still in clinical stage with no current revenue streams
- Success depends on pending partnerships and licensing deals
- Operating in early-stage exosome market with unproven technology
ORLANDO, FL / ACCESS Newswire / April 17, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share guidance on the new subdivisions it is forming.
Exousia Pro has stated that its primary focus is advancing cancer therapies with its exosomes, but this is only a small segment of the exosome market. The Company has decided to create multiple subsidiaries to engage in these activities and expand the use of our plant-based exosomes.
The subdivisions will operate as wholly owned subsidiaries, independent of each other.
Biotech - This subdivision will create new therapies using exosomes, focusing on cancer.
Cosmeceutical - This subdivision will focus on using exosomes in the multi-billion-dollar skincare industry. Exousia Pro is finalizing two studies using our plant-based exosomes in skincare treatments.
Nutraceutical - This division will work on adding exosomes to certain anti-aging supplements, IV therapies, tinctures, and peptides. The consensus global market estimate ranges from
Exousia Pro will soon enter each market through joint ventures with companies already operating in each space. By adding our plant-based exosomes, we will enhance their products by speeding up their entry into the blood system while contributing the perceived healing properties naturally inherent in the plant-based exosomes.
Exousia Pro has four additional markets it plans to enter once an anticipated licensing deal for additional patents is completed. Negotiations are in the final stages and a definitive agreement is expected to be completed in the near future.
Matt Dwyer, President of Exousia Pro, stated, "The Company is very excited to be entering these new markets and the others on the horizon. With the exosome market in its infancy, Exousia Pro and our plant-based exosomes are at the forefront of partnering with existing products and therapies to enhance their effectiveness."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What are the three new subdivisions announced by Exousia Pro (MAJI)?
How large is the nutraceutical market that MAJI is entering?
What is Exousia Pro's (MAJI) strategy for entering new markets?
How many additional markets does MAJI plan to enter after the licensing deal?
